Don Bailey - Lineage Cell Independent Director
| LCTX Stock | ILA 386.80 31.00 7.42% |
Insider
Don Bailey is Independent Director of Lineage Cell Therapeutics, since 2019.
| Age | 73 |
| Tenure | 5 years |
| Phone | 442 287 8990 |
| Web | http://www.lineagecell.com |
Lineage Cell Management Efficiency
The company has return on total asset (ROA) of (13.19) % which means that it has lost $13.19 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (10.82) %, meaning that it generated substantial loss on money invested by shareholders. Lineage Cell's management efficiency ratios could be used to measure how well Lineage Cell manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Amir Brami | Ratio Oil Explorations | N/A | |
| Yossi Shazar | Ratio Oil Explorations | N/A | |
| Nirit Zeevi | Azrieli Group | 44 | |
| Eyal Henkin | Azrieli Group | 54 | |
| Moshe Kaplinsky | Elbit Systems | 62 | |
| Lena Schwartz | Israel Discount Bank | N/A | |
| Moran Goder | Azrieli Group | N/A | |
| Dani Ashkenazi | Tower Semiconductor | 60 | |
| Bilha Shapira | Elbit Systems | 66 | |
| Assaf Eldar | Israel Discount Bank | 48 | |
| Yaacov Kagan | Elbit Systems | N/A | |
| David Paulson | Bank Leumi Le Israel | 60 | |
| Terry Yaskil | Mizrahi Tefahot | 50 | |
| Yigal Landau | Ratio Oil Explorations | 63 | |
| Aviram Lahav | ICL Israel Chemicals | 64 | |
| Eliav David | Bank Leumi Le Israel | N/A | |
| Liran Razmovich | Israel Discount Bank | N/A | |
| Rami Myerson | Elbit Systems | N/A | |
| Aya Landman | ICL Israel Chemicals | N/A | |
| Amir Meshulam | ICL Israel Chemicals | 43 | |
| Gil Rogozinski | Ratio Oil Explorations | 53 | |
Management Performance
| Return On Equity | -10.82 | |||
| Return On Asset | -13.19 |
Lineage Cell Therape Leadership Team
Elected by the shareholders, the Lineage Cell's board of directors comprises two types of representatives: Lineage Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lineage. The board's role is to monitor Lineage Cell's management team and ensure that shareholders' interests are well served. Lineage Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lineage Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Mulroy, Independent Director | ||
| Alfred Kingsley, Chairman of the Board, Director | ||
| Stephana Patton, Compliance Officer, Corporate Secretary | ||
| Alexandra Hernandez, Senior Director of Finance, Controller, Interim Principal Accounting Officer | ||
| Deborah Andrews, Independent Director | ||
| Chase Leavitt, General Counsel and Corporate Secretary | ||
| Don Bailey, Independent Director | ||
| Brian Culley, Chief Executive Officer, Interim Chief Financial Officer, Director | ||
| Brandi Roberts, Chief Financial Officer, Senior Vice President - Finance | ||
| Gary Hogge, Senior Vice President of Clinical & Medical Affairs | ||
| Neal Bradsher, Independent Director | ||
| Angus Russell, Independent Director | ||
| Edward Wirth, Chief Medical Officer | ||
| Stephen Farrell, Independent Director |
Lineage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lineage Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.82 | |||
| Return On Asset | -13.19 | |||
| Current Valuation | 1.3 B | |||
| Shares Owned By Insiders | 4.50 % | |||
| Shares Owned By Institutions | 43.81 % | |||
| Revenue | 1.83 M | |||
| Gross Profit | 1.44 M | |||
| EBITDA | (24.77 M) | |||
| Net Income | (11.93 M) | |||
| Cash And Equivalents | 68.75 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lineage Cell in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lineage Cell's short interest history, or implied volatility extrapolated from Lineage Cell options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics,. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Lineage Stock analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |